Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Sapacitabine|DRUG: Olaparib
Sponsor: Dana-Farber Cancer Institute
Collaborators: AstraZeneca|Cyclacel Pharmaceuticals, Inc.